ZEVRA THERAPEUTICS, INC.ZVRAEarnings & Financial Report
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
Revenue
$26.1M
Gross Profit
N/A
Operating Profit
$4.1M
Net Profit
$-544.0K
Gross Margin
N/A
Operating Margin
15.9%
Net Margin
-2.1%
YoY Growth
605.4%
EPS
$-0.01
ZEVRA THERAPEUTICS, INC. Q3 FY2025 Financial Summary
ZEVRA THERAPEUTICS, INC. reported revenue of $26.1M (up 605.4% YoY) for Q3 FY2025, with a net profit of $-544.0K (up 98.4% YoY) (-2.1% margin).
Key Financial Metrics
| Total Revenue | $26.1M |
|---|---|
| Net Profit | $-544.0K |
| Gross Margin | N/A |
| Operating Margin | 15.9% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
ZEVRA THERAPEUTICS, INC. Q3 FY2025 revenue of $26.1M breaks down across 3 segments, led by MIPLYFFA at $22.4M (85.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| MIPLYFFA | $22.4M | 85.9% |
| Arimoclomol Purchase Agreement | $2.4M | 9.2% |
| Other | $1.3M | 4.8% |
ZEVRA THERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
ZEVRA THERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as MIPLYFFA and Arimoclomol Purchase Agreement) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| MIPLYFFA | $26.4M | $22.4M | $21.5M | $17.1M |
| Arimoclomol Purchase Agreement | $5.7M | $2.4M | $2.6M | $2.3M |
| Other | $2.0M | $1.3M | $1.8M | $1.0M |
ZEVRA THERAPEUTICS, INC. Annual Revenue by Year
ZEVRA THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $106.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $106.5M |
| 2024 | $23.6M |
| 2023 | $27.5M |
| 2022 | $10.2M |
ZEVRA THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
ZEVRA THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $34.1M | +183.4% | N/A | N/A |
| Q3 FY2025 | $26.1M | +605.4% | $-544.0K | -2.1% |
| Q2 FY2025 | $25.9M | +481.7% | $74.7M | 288.7% |
| Q1 FY2025 | $20.4M | +495.6% | $-3.1M | -15.2% |
| Q4 FY2024 | $12.0M | -6.8% | N/A | N/A |
| Q3 FY2024 | $3.7M | +27.6% | $-33.2M | -899.2% |
| Q2 FY2024 | $4.4M | -47.5% | $-19.9M | -447.9% |
| Q1 FY2024 | $3.4M | +7.8% | $-16.6M | -485.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $4.4M | $3.7M | $12.0M | $20.4M | $25.9M | $26.1M | $34.1M |
| YoY Growth | 7.8% | -47.5% | 27.6% | -6.8% | 495.6% | 481.7% | 605.4% | 183.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $151.3M | $144.4M | $191.6M | $178.1M | $172.7M | $256.3M | $270.1M | $284.7M |
| Liabilities | $102.5M | $111.9M | $121.8M | $138.5M | $131.7M | $139.0M | $137.0M | $130.1M |
| Equity | $48.8M | $32.5M | $69.8M | $39.7M | $41.0M | $117.2M | $133.2M | $154.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.2M | $-19.1M | $-18.1M | $-16.3M | $-8.2M | $-3.6M | $4.7M | $5.5M |